glp 1 compounding news Zepbound copycats remain online despite FDA ban Non-Traditional Channels: The Compounded GLP-1

Lab Invest 98 , 714 (2018)

doi: 10.1093/treephys/21.1.1 20 HuB.ZhaoJ

Drug interactions and monitoring strategies should be incorporated into clinical management plans

Lilly is building a multi-engine growth machine: Alzheimer's Treatment Kisunla (Donanemab) - FDA-approved for early Alzheimer's, first proven to slow cognitive decline Represents a breakthrough in neurodegenerative disease treatment Oncology & Immunology Verzenio (breast cancer): $1.47B in Q3 2025 (+7% YoY) Jaypirca and Omvoh expanding in oncology and autoimmune markets Radiopharmaceutical investments through Point Biopharma ($1.4B acquisition) and Aktis Oncology partnership Pipeline Depth 40+ programs in Phase 2/3 across neuroscience, immunology, and cardiology Recent acquisitions: Scorpion Therapeutics, SiteOne Therapeutics, Adverum Biotechnologies Lilly isn't a one-trick pony

(2017) MicroRNA-22 suppresses the growth, migration and invasion of colorectal cancer cells through a Sp1 negative feedback loop, Oncotarget , 8 , 36266-36278, doi: Dhar, S., Kumar, A., Gomez, C

The warning also notes that serious neuropsychiatric issues linked to bupropion have been reported